相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MOVING IMMUNE THERAPY FORWARD TARGETING TME
Kayla F. Goliwas et al.
PHYSIOLOGICAL REVIEWS (2021)
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
Egle Ramelyte et al.
CANCER CELL (2021)
Immunomodulation by targeted anticancer agents
Giulia Petroni et al.
CANCER CELL (2021)
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
Elly Marcq et al.
CANCERS (2021)
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model
Yue Zhao et al.
HEPATOLOGY (2021)
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment
Julie Lang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy
Xiuyun Lin et al.
CANCER BIOLOGY & THERAPY (2020)
Immunology-Guided Biomaterial's Design as Mucosal Cancer Vaccine
Shiran Ferber et al.
ADVANCED MATERIALS (2020)
Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma
Bongkum Choi et al.
CANCER LETTERS (2020)
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
Matthew Kraman et al.
CLINICAL CANCER RESEARCH (2020)
Alteration of CD226/TIGIT immune checkpoint on T cells in the pathogenesis of primary Sjogren's syndrome
Chuiwen Deng et al.
JOURNAL OF AUTOIMMUNITY (2020)
Characterization of human cancer xenografts in humanized mice
Jonathan Rios-Doria et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma Pooled Analysis of 3 Clinical Trials
Igor Puzanov et al.
JAMA ONCOLOGY (2020)
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-novel approaches and future outlook
Lena Horvath et al.
MOLECULAR CANCER (2020)
Memory CD8+ T cell responses to cancer
Jichang Han et al.
SEMINARS IN IMMUNOLOGY (2020)
Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+humanized mouse model
Nahee Park et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack et al.
FRONTIERS IN IMMUNOLOGY (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
TIM3 comes of age as an inhibitory receptor
Yochai Wolf et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization (vol 175, pg 313, 2018)
Miguel F. Sanmamed et al.
CELL (2019)
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf et al.
LANCET ONCOLOGY (2019)
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
A. Capasso et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
Aude Burlion et al.
ONCOIMMUNOLOGY (2019)
TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia
Xiaole Zhang et al.
CELLULAR IMMUNOLOGY (2019)
Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC
Jose Carlos Benitez et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Amy L. Shergold et al.
PHARMACOLOGICAL RESEARCH (2019)
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Ismail M. Meraz et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
Seiji Okada et al.
CELLS (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Lawrence P. Andrews et al.
NATURE IMMUNOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Sema Kurtulus et al.
IMMUNITY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models
Kyoung Ho Pyo et al.
LUNG CANCER (2019)
TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Srimoyee Ghosh et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
Lukasz Kuryk et al.
ONCOIMMUNOLOGY (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy
Minan Wang et al.
FASEB JOURNAL (2018)
Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy
Yue Zhao et al.
GUT (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Humanized Mice for the Study of Immuno-Oncology
Philippe De La Rochere et al.
TRENDS IN IMMUNOLOGY (2018)
Tumor-infiltrating CD8+and FOXP3+lymphocytes before and after neoadjuvant chemotherapy in cervical cancer
Yun Liang et al.
DIAGNOSTIC PATHOLOGY (2018)
Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy
Shouheng Lin et al.
MABS (2018)
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Takumi Maruhashi et al.
NATURE IMMUNOLOGY (2018)
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Jinfang Zhang et al.
TRENDS IN BIOCHEMICAL SCIENCES (2018)
Mouse Models for Cancer Immunotherapy Research
Brian Olson et al.
CANCER DISCOVERY (2018)
Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
Junhun Cho et al.
ESMO OPEN (2018)
Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
Roberto R. Rosato et al.
BREAST CANCER RESEARCH (2018)
Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis
Chiaki Iwamura et al.
BLOOD (2017)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Singlicate Ligand Binding Assay Using an Automated Microfluidic System: a Clinical Case Study
Hao Jiang et al.
AAPS JOURNAL (2017)
Bioactive poly(ethylene glycol) hydrogels to recapitulate the HSC niche and facilitate HSC expansion in culture
Maude L. Cuchiara et al.
BIOTECHNOLOGY AND BIOENGINEERING (2016)
Cancer Neoantigens and Applications for Immunotherapy
Alexis Desrichard et al.
CLINICAL CANCER RESEARCH (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer
Takahiro Hasegawa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Marcel A. Deken et al.
ONCOIMMUNOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
D. Massi et al.
ANNALS OF ONCOLOGY (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
Jennifer A. Wargo et al.
SEMINARS IN ONCOLOGY (2015)
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
Weiqing Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
Darya Alizadeh et al.
CANCER RESEARCH (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Benedetto Farsaci et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Beyond DNA repair, the immunological role of PARP-1 and its siblings
Maria Manuela Rosado et al.
IMMUNOLOGY (2013)
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia C. Formenti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion
Nicolas Legrand et al.
JOURNAL OF GENERAL VIROLOGY (2012)
Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rγnull humanized mice
Eva Billerbeck et al.
BLOOD (2011)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
分享论文
